ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0166

Digital Extensor Paratenonitis Is Frequent in Early Rheumatoid Arthritis

Mihaela Maruseac1, Adrien NZEUSSEU TOUKAP2 and Maria S. Stoenoiu3, 1Rheumatology department, Cliniques Universitaires Saint-Luc, Brussel, Belgium, 2Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium, 3Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium

Meeting: ACR Convergence 2021

Keywords: extra-synovial, Imaging, rheumatoid arthritis, tendon, Ultrasound

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Imaging of Rheumatic Diseases Poster (0149–0182)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Finger extensor tendon involvement (FEP) or paratenonitis has previously been described by ultrasound (US) in patients suffering from early psoriatic arthritis. Contradictory results were published in patients suffering from rheumatoid arthritis.

We aimed to assess the involvement of FEP in early rheumatoid arthritis (ERA) patients and in asymptomatic subjects.

Methods: Inclusion criteria for ERA patients were: symptom duration < 6 months prior to ERA diagnosis; age >18 years; no DMARD treatment at time of US examination. Inclusion criteria for asymptomatic subjects group were: age >18 years; no other known rheumatic disease (connective tissue diseases, rheumatoid, psoriatic arthritis, spondyloarthritis, hand osteoarthritis, gout, chondrocalcinosis); no psoriasis, no inflammatory bowel diseases. Patients were evaluated clinically (44-tender and 44-swollen joint count), and answered health assessment questionnaires (HAQ). Hand, wrist, feet X-ray and laboratory tests including anti-citrullinated protein antibodies (ACPA), rheumatoid factor (RF) and C-reactive protein (CRP) were performed in all patients. US assessments were performed blinded to clinical and laboratory data. FEP was assessed in longitudinal and in transverse view at all metacarpophalangeal (MCP) joints and proximal phalangeal joints, both in grey-scale and Doppler mode. FEP was defined as abnormal anechoic and/or hypoechoic (relative to tendon fibers) paratenon widening seen in two perpendiculars planes and was scored as present/absent.

Results: One hundred and four consecutive ERA patients and 44 asymptomatic subjects were included in this study. Mean age and comparable gender distribution were observed between the groups (50.1±1.3 y, ERA vs. 45.8±2.0 y, asymptomatic subjects). ACPA were present in 63.5%, RF in 62.5%, tobacco use in 22.1% and x-ray bone erosions in 33.7% of ERA patients. Age, gender, delay between the first symptom and diagnosis, SDAI, CDAI, CRP level, HAQ did not differ significantly between patients with FEP involvement and those without. FEP was present in two-third of ERA patients and absent in asymptomatic subjects (60.6% vs. 0%, p< 0.001). In univariate analysis, the presence of FEP was significantly associated with the presence of MCP erosion (p=0.02), ACPA positivity (p=0.017), rheumatoid factor (p=0.009) and tobacco use (p=0.015). In multivariate analysis, the presence of FEP was significantly associated with the presence of MCP erosions, ACPA positivity and tobacco use (p< 0.01).

Conclusion: FEP is relatively frequent in ERA patients and it is not present in asymptomatic subjects. Our results show that FEP is associated with ACPA positivity and bone erosions, thus identifying patients early with a possibly more aggressive or severe disease.


Disclosures: M. Maruseac, None; A. NZEUSSEU TOUKAP, Abbvie, 1, 5, Eli Lilly, 1, 5, Janssen, 1, 5, UCB, 1, 5, Celgene, 1, 5, Pfizer, 1, 5; M. Stoenoiu, AbbVie, 2, 5, 6, UCB, 2, 5, 6, Pfizer, 2, 5, 6, MSD, 2, 5, 6, Roche, 2, 5, 6.

To cite this abstract in AMA style:

Maruseac M, NZEUSSEU TOUKAP A, Stoenoiu M. Digital Extensor Paratenonitis Is Frequent in Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/digital-extensor-paratenonitis-is-frequent-in-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/digital-extensor-paratenonitis-is-frequent-in-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology